Evaluating Balcinrenone and Dapagliflozin for Heart Failure with Kidney Issues
Official title: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function
Run by AstraZeneca · NCT06307652 · Data updated 2026-11-12
This study is testing if a combination of two medications, balcinrenone and dapagliflozin, can help people with heart failure and kidney problems feel better compared to taking dapagliflozin alone.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 130 Years |
| Sex | All |
| Enrollment | 3850 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 852 sites (Alexander City, Alabama and 851 other locations) |
| Status | Recruiting |
| Started | April 12, 2024 |
| Main results expected | April 16, 2027 |
| Study ends | April 16, 2027 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT06307652 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with symptomatic heart failure, recent heart failure events, and impaired kidney function.
✕Probably not a fit
Patients with acute coronary syndrome, recent major cardiac surgeries, or specific heart conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase III clinical trial investigates the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients suffering from chronic heart failure and impaired kidney function. Participants will be randomly assigned to receive one of three treatment regimens, including varying doses of balcinrenone/dapagliflozin or dapagliflozin with matching placebos. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events over an average duration of 22 months. Conducted across approximately 700 sites in 40 countries, this trial seeks to provide insights into effective management strategies for patients with these conditions.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with heart failure and impaired kidney function, potentially reducing cardiovascular deaths and heart failure events.
How similar studies have gone: Other studies have shown promise in treating heart failure with similar approaches, but this specific combination is being evaluated for the first time.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Documented diagnosis of symptomatic HF (NYHA functional class II-IV) * Having had a recent HF event within 6 months (hospitalization or urgent visit) * Have a LVEF value from an assessment within the last 12 months * Managed with SoC therapy for HF and renal impairment according to local guidelines * NT-proBNP must be \>300 pg/mL (\>600 pg/mL if concomitant atrial fibrillation or atrial flutter) * Not taking an MRA * An eGFR ≥ 20 to \< 60 mL/min/1.73 m2 * Serum/plasma potassium ≤ 5.0 mmol/L Exclusion Criteria: * Acute coronary syndrome (unstable angina or myocardial infarction), stroke or transient ischaemic attack within the previous 3 months prior to enrolment or during the screening period * Major cardiac surgery, coronary revascularisation or valvular repair or replacement, or implantation of a Cardiac resynchronisation therapy device within 3 months prior to enrolment or during the screening period, or planned to undergo any of these operations * History of hypertrophic obstructive cardiomyopathy * Complex congenital heart disease or severe uncorrected primary valvular disease * Symptomatic bradycardia or second- or third-degree heart block without a pacemaker * Systolic BP \< 90 mmHg, or symptomatic hypotension within the past 24 hours * Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD or exacerbation of COPD requiring invasive mechanical ventilation assistance within 12 months prior to enrolment * Type 1 diabetes mellitus * Kidney replacement therapy in the past 4 weeks, currently requiring kidney replacement or imminent plan to start kidney replacement therapy * Acute or chronic liver disease with severe impairment of liver function, eg, ascites, oesophageal varices, coagulopathy, and encephalopathy * Suspected or confirmed COVID-19 infection within the last 4 weeks or hospitalisation for COVID-19 within the last 12 weeks * Treatment with strong or moderate CYP3A4 inhibitor or inducer
Where it's running
-
Research Site
Alexander City, Alabama, United States Recruiting -
Research Site
Fairhope, Alabama, United States Recruiting -
Research Site
Huntsville, Alabama, United States Recruiting -
Research Site
Phoenix, Arizona, United States Recruiting -
Research Site
Phoenix, Arizona, United States Recruiting -
Research Site
Little Rock, Arkansas, United States Recruiting
Show 44 more locations
-
Research Site
Beverly Hills, California, United States Recruiting -
Research Site
Covina, California, United States Recruiting -
Research Site
Los Angeles, California, United States Recruiting -
Research Site
Los Angeles, California, United States Recruiting -
Research Site
Redding, California, United States Recruiting -
Research Site
San Diego, California, United States Recruiting -
Research Site
San Francisco, California, United States Recruiting -
Research Site
Vista, California, United States Recruiting -
Research Site
West Hills, California, United States Recruiting -
Research Site
Aurora, Colorado, United States Recruiting -
Research Site
Boca Raton, Florida, United States Recruiting -
Research Site
Bradenton, Florida, United States Recruiting -
Research Site
Delray Beach, Florida, United States Recruiting -
Research Site
Fort Lauderdale, Florida, United States Recruiting -
Research Site
Gainesville, Florida, United States Recruiting -
Research Site
Jacksonville, Florida, United States Recruiting -
Research Site
Miami, Florida, United States Recruiting -
Research Site
Miami Lakes, Florida, United States Recruiting -
Research Site
Palm Beach Gardens, Florida, United States Recruiting -
Research Site
Pensacola, Florida, United States Recruiting -
Research Site
Safety Harbor, Florida, United States Recruiting -
Research Site
Saint Augustine, Florida, United States Recruiting -
Research Site
St. Petersburg, Florida, United States Recruiting -
Research Site
Tampa, Florida, United States Recruiting -
Research Site
Atlanta, Georgia, United States Recruiting -
Research Site
Peachtree City, Georgia, United States Recruiting -
Research Site
Tucker, Georgia, United States Recruiting -
Research Site
Chicago, Illinois, United States Recruiting -
Research Site
Hazel Crest, Illinois, United States Recruiting -
Research Site
Peoria, Illinois, United States Recruiting -
Research Site
Winfield, Illinois, United States Recruiting -
Research Site
Elkhart, Indiana, United States Recruiting -
Research Site
Evansville, Indiana, United States Recruiting -
Research Site
Muncie, Indiana, United States Recruiting -
Research Site
Munster, Indiana, United States Recruiting -
Research Site
Waterloo, Iowa, United States Recruiting -
Research Site
Wichita, Kansas, United States Recruiting -
Research Site
West Monroe, Louisiana, United States Recruiting -
Research Site
Rockville, Maryland, United States Recruiting -
Research Site
Boston, Massachusetts, United States Recruiting -
Research Site
Bloomfield Hills, Michigan, United States Recruiting -
Research Site
Ypsilanti, Michigan, United States Recruiting -
Research Site
Saint Paul, Minnesota, United States Recruiting -
Research Site
Jackson, Mississippi, United States Recruiting
+802 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.